BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development
company, announced today that two Notices of Allowance have been issued
by the United States Patent and Trademark Office (USPTO) for BL-1021, an
orally available small molecule for treating neuropathic pain. The first
has been issued for a patent application claiming BL-1021's composition,
that when issued, will be valid until at least September 2022.
Additional patents claiming BL-1021's composition are granted or pending
in Europe, Japan, Canada, Korea, Mexico, Israel, India, China and
Australia. The other Notice of Allowance is for a patent application
claiming the use of BL-1021 for the treatment of pain, that when issued,
will be valid until at least January 2028. Additional patents claiming
the use of BL-1021 for the treatment of pain are pending in Europe,
Japan, Canada, Korea, Mexico, Israel, India, China and Australia.
"We are very pleased at receiving these notices of allowance from the
USPTO for the patent applications covering BL-1021's composition and
use," stated Dr. Kinneret Savitsky, BioLineRx's CEO. "Currently millions
of people around the world suffer from neuropathic pain resulting from
diabetes, shingles and other diseases and present treatments do not give
them a satisfactory solution. BL-1021 may present an improved treatment
for such patients, greatly improving their quality of life."
Physical activity and positive affect boost cognition in women with fibromyalgia despite pain